Key result
Simulated delay-dependent remedial dosing optimizes edoxaban exposure after missed doses compared to standard guidance.
Why the study?
Adherence to edoxaban therapy in NVAF patients is unsatisfactory and current remedial dosing recommendations lack strong evidence support.
Do specific model-informed remedial dosing strategies improve PK/PD parameters compared to EHRA recommendations for delayed or missed edoxaban doses in NVAF patients?
Do specific model-informed remedial dosing strategies improve PK/PD parameters compared to EHRA recommendations for delayed or missed edoxaban doses in NVAF patients?
PK/PD modeling suggests that optimal remedial dosing for missed edoxaban depends on the delay time, challenging current generic EHRA recommendations.
Answers are grounded in this paper and cite their sources.
Simulation-based remedial edoxaban regimens for NVAF non-adherence require clinical validation before use; leaves open evidence-based guidance pending prospective trials.
AIMS: Edoxaban is a non-vitamin K antagonist oral anticoagulant (NOAC) widely used for the long-term prevention of stroke in patients with non-valvular atrial fibrillation (NVAF). Adherence to NOAC therapy has been unsatisfactory and decreases over time. Remedial strategies are currently used to address the non-adherence events. Current recommendations, however, are generic and not well supported by evidence. The aim of this study was to explore appropriate remedial dosing regimens for non-adherent edoxaban-treated NVAF patients through Monte Carlo simulation. METHODS: Six regimens were compared with the current recommendations of the European Heart Rhythm Association (EHRA) guide based on total deviation time. Both edoxaban plasma concentration and intrinsic Factor Xa activity were considered. Monte Carlo simulations were performed using RxODE based on a published population pharmacokinetic/pharmacodynamic (PK/PD) model. RESULTS: The proposed remedial strategies were different than the EHRA recommendations and were related to the delay time. However, it was found that the missed dose can be administered immediately if the delay time is within 11 h. When the delay is between 12 and 19 h, a half dose followed by a regular dosing schedule is recommended. When the delay time exceeds 19 h, a full dose followed by a half dose is preferred. CONCLUSION: PK/PD modelling and simulation are effective in developing and evaluating the remedial strategies of edoxaban, which can help maximise its therapeutic effect.
No takes yet. Share an insight, caveat, or question.
Yin et al. (2022) studied Non-valvular atrial fibrillation. Remedial dosing regimens for delayed or missed edoxaban doses vs. European Heart Rhythm Association (EHRA) recommendations was evaluated on Total deviation time based on edoxaban plasma concentration and intrinsic Factor Xa activity. Simulated remedial dosing for missed edoxaban suggests immediate administration for delays up to 11 hours, a half dose for 12-19 hours, and a full then half dose for delays over 19 hours.
Synapse has enriched 10 related papers. Consider them for comparative context: